Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 9/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.44 |
| ▸ | MEN1 | O00255 | 8/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.44 |
| ▸ | USP2 | O75604 | 8/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.44 |
| ▸ | TSHR | P16473 | 6/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 6/20 | 0.42 |
| ▸ | LMNA | P02545 | 6/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.42 |
| ▸ | PDE5A | O76074 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6494390 | 0.86 | MEN1 (0.41) | MEN1KMT2ATSHRHSD17B10MAPT | |
| SCHEMBL5462036 | 0.85 | KMT2A (0.48) | CYP1A2CYP3A4CYP2D6MEN1KMT2A | |
| SCHEMBL6488993 | 0.84 | ALDH1A1 (0.51) | CYP1A2CYP3A4CYP2D6MEN1KMT2A | |
| SCHEMBL6480107 | 0.83 | ADORA3 (0.46) | CYP1A2CYP3A4CYP2D6MEN1KMT2A | |
| SCHEMBL6491520 | 0.79 | KMT2A (0.46) | CYP1A2CYP3A4CYP2D6MEN1KMT2A | |
| SCHEMBL5462040 | 0.78 | ADORA3 (0.42) | CYP1A2CYP3A4MEN1KMT2ACYP2C19 | |
| SCHEMBL6481975 | 0.76 | MEN1 (0.33) | CYP1A2CYP3A4CYP2D6MEN1KMT2A | |
| SCHEMBL939939 | 0.75 | MAPT (0.41) | CYP1A2CYP3A4CYP2D6MEN1KMT2A | |
| SCHEMBL3529460 | 0.74 | KMT2A (0.50) | CYP1A2CYP3A4CYP2D6MEN1KMT2A | |
| SCHEMBL5224357 | 0.74 | KMT2A (0.47) | CYP1A2CYP3A4CYP2D6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390349-B1 | AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI SA (FR) | 2012-07-25 | — | — | EP | disclosed |
| CN-1257160-C | Aminoquinoline derivatives and their use as adenosine A3 ligands | PASTEUR SANOFI DIAGNOSTICS (FR) | 2006-05-24 | — | — | CN | disclosed |
| US-6969723-B2 | Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands | SANOFI - AVENTIS (FR) | 2005-11-29 | — | — | US | disclosed |
| US-6844342-B2 | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-01-18 | — | — | US | disclosed |
| US-20040186133-A1 | Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands | SANOFI (FR) | 2004-09-23 | — | — | US | disclosed |
| US-6774134-B2 | FOR THERAPY OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-10 | — | — | US | disclosed |
| CN-1512985-A | Aminoquinoline and aminopiperidine derivatives and their use as adenosine A3 ligands | ��ŵ�Ѻϳ�ʵ���� | 2004-07-14 | — | — | CN | disclosed |
| US-20040067997-A1 | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents | YU KUO-LONG (US) | 2004-04-08 | — | — | US | disclosed |
| US-20020099208-A1 | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents | BRISTOL-MYERS SQUIBB COMPANY | 2002-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099208-A1 | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents | MAVS, ZC3HAV1, EIF2AK2 | CYP1A2 1326/4885CYP3A4 217/4885CYP2D6 1122/4885 |
| US-20040067997-A1 | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents | MAVS, ZC3HAV1, EIF2AK2 | CYP1A2 1326/4885CYP3A4 217/4885CYP2D6 1122/4885 |
| US-20040186133-A1 | Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands | ADORA3, ADORA1, ADORA2A | CYP1A2 564/4885CYP3A4 247/4885CYP2D6 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.